Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC.

Ann Oncol. 2018 Feb 23. doi: 10.1093/annonc/mdy076. [Epub ahead of print]

PMID:
29788155
2.

Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):211-221. doi: 10.1002/psp4.12075. Epub 2016 Apr 14.

3.

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.

Stewart CF, Tagen M, Schwartzberg LS, Blakely LJ, Tauer KW, Smiley LM.

Cancer Chemother Pharmacol. 2014 Mar;73(3):561-8. doi: 10.1007/s00280-014-2385-0. Epub 2014 Jan 22.

4.

A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.

Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C.

Pediatr Blood Cancer. 2013 Apr;60(4):627-32. doi: 10.1002/pbc.24309. Epub 2012 Sep 21.

5.

Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.

Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW.

Cancer. 2012 Nov 15;118(22):5663-70. doi: 10.1002/cncr.27563. Epub 2012 Apr 19.

6.

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK.

Clin Cancer Res. 2012 May 1;18(9):2679-86. doi: 10.1158/1078-0432.CCR-11-3201. Epub 2012 Mar 15.

7.

Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.

Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075. Epub 2011 Apr 20.

8.

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF.

Clin Cancer Res. 2011 Jan 1;17(1):89-99. doi: 10.1158/1078-0432.CCR-10-1934. Epub 2010 Nov 18.

9.

IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells.

Kempuraj D, Conti P, Vasiadi M, Alysandratos KD, Tagen M, Kalogeromitros D, Kourelis T, Gregoriou S, Makris M, Stavrianeas NG, Theoharides TC.

Eur J Dermatol. 2010 Nov-Dec;20(6):865-7. doi: 10.1684/ejd.2010.1110. Epub 2010 Nov 4. No abstract available.

10.

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF.

Drug Metab Dispos. 2011 Jan;39(1):15-21. doi: 10.1124/dmd.110.035915. Epub 2010 Oct 14.

11.

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.

Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, Pai Panandiker AS, Leung W, Chin TK, Stewart CF, Kocak M, Rowland C, Merchant TE, Kaste SC, Gajjar A.

J Clin Oncol. 2010 Nov 1;28(31):4762-8. doi: 10.1200/JCO.2010.30.3545. Epub 2010 Oct 4. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5351. Panandiker, Atmaram Pai [corrected to Pai Panandiker, Atmaram S].

12.

Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS).

Bai F, Tagen M, Colotta C, Miller L, Fouladi M, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52. doi: 10.1016/j.jchromb.2010.07.019. Epub 2010 Jul 30. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Nov 1;908:161.

13.

Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.

McKibbin T, Zhao W, Tagen M, Daw NC, Furman WL, McGregor LM, Geyer JR, Allen JW, Stewart CF.

Eur J Cancer. 2010 Jul;46(11):2045-51. doi: 10.1016/j.ejca.2010.05.007. Epub 2010 Jun 4.

14.

P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P, Fraga CH, Panetta JC, Waters CM, Stewart CF.

Drug Metab Lett. 2010 Dec;4(4):195-201.

15.

IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4448-53. doi: 10.1073/pnas.1000803107. Epub 2010 Feb 16.

16.

Stability of cyclophosphamide in extemporaneous oral suspensions.

Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF.

Ann Pharmacother. 2010 Feb;44(2):295-301. doi: 10.1345/aph.1M578. Epub 2010 Jan 26.

17.

Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).

Bai F, Zhu F, Tagen M, Miller L, Owens TS, Mallari J, Derrick E, Zhang F, Stewart CF.

J Pharm Biomed Anal. 2010 Mar 11;51(4):915-20. doi: 10.1016/j.jpba.2009.10.016. Epub 2009 Oct 30.

18.

Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content.

Tagen M, Elorza A, Kempuraj D, Boucher W, Kepley CL, Shirihai OS, Theoharides TC.

J Immunol. 2009 Nov 15;183(10):6313-9. doi: 10.4049/jimmunol.0803422. Epub 2009 Oct 21.

19.

Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection.

Hubbard KE, Wells A, Owens TS, Tagen M, Fraga CH, Stewart CF.

Biomed Chromatogr. 2010 Jun;24(6):626-31. doi: 10.1002/bmc.1338.

PMID:
19810006
20.

Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF.

Cancer Res. 2009 Jul 15;69(14):5885-92. doi: 10.1158/0008-5472.CAN-09-0700. Epub 2009 Jun 30.

21.

Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS).

Bai F, Fraga CH, Tagen M, Schaiquevich P, Hagedorn N, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jun 15;877(18-19):1709-15. doi: 10.1016/j.jchromb.2009.04.025. Epub 2009 Apr 24.

22.

Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.

Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolfberg A, Theoharides TC.

Br J Pharmacol. 2008 Dec;155(7):1076-84. doi: 10.1038/bjp.2008.356. Epub 2008 Sep 22.

23.

Role of mast cells in tumor growth.

Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC.

Ann Clin Lab Sci. 2007 Autumn;37(4):315-22. Review.

PMID:
18000287
24.

Anti-chemokine therapy for inflammatory diseases.

Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC, Cerulli G, Salini V, Neri G.

Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):447-53. Review.

PMID:
17880758
25.

Differential release of mast cell mediators and the pathogenesis of inflammation.

Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D.

Immunol Rev. 2007 Jun;217:65-78. Review. Erratum in: Immunol Rev. 2007 Oct;219:204.

PMID:
17498052
26.

Skin corticotropin-releasing hormone receptor expression in psoriasis.

Tagen M, Stiles L, Kalogeromitros D, Gregoriou S, Kempuraj D, Makris M, Donelan J, Vasiadi M, Staurianeas NG, Theoharides TC.

J Invest Dermatol. 2007 Jul;127(7):1789-91. Epub 2007 Mar 1. No abstract available.

27.

Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions.

Theoharides TC, Kempuraj D, Tagen M, Vasiadi M, Cetrulo CL.

Stem Cell Rev. 2006;2(2):143-54. Review.

PMID:
17237553
28.

Immunological activation of human umbilical cord blood mast cells induces tryptase secretion and interleukin-6, and histidine decarboxilase mRNA gene expression.

Castellani ML, Perrella A, Kempuraj DJ, Boucher W, Tagen M, Salini V, Vecchiet J, Tetè S, Frydas S, Theoharides TC, Conti P.

Pharmacol Res. 2007 Jan;55(1):57-63. Epub 2006 Oct 20.

PMID:
17110126
29.

The proinflammatory interleukin-21 elicits anti-tumor response and mediates autoimmunity.

Castellani ML, Salini V, Frydas S, Donelan J, Tagen M, Madhappan B, Petrarca C, Falasca K, Neri G, Tete S, Vecchiet J.

Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):247-51. No abstract available.

PMID:
16831291
30.

Chronic fatigue syndrome, mast cells, and tricyclic antidepressants.

Theoharides TC, Papaliodis D, Tagen M, Konstantinidou A, Kempuraj D, Clemons A.

J Clin Psychopharmacol. 2005 Dec;25(6):515-20. No abstract available.

PMID:
16282830

Supplemental Content

Support Center